Amarin Corporation plc
AMRNHealthcareNASDAQDrug Manufacturers - General · Last scanned Oct 23, 2026
Scan Results
Daily timeframePart of the healthcare sector, Amarin Corporation plc (AMRN) is listed under Drug Manufacturers - General. The $243.2M market capitalization puts AMRN squarely in micro-cap range for its industry. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Market Cap
$243.2M
Beta
0.77
P/E (TTM)
—
P/E (Fwd)
11.84
EPS (TTM)
$-1.20
EPS (Fwd)
$0.98
ROE
-6.0%
ROA
-2.3%
Cash
$314.6M
Total Debt
$7.2M
Free CF
-$5.6M
52W Change
-40.4%
Annual Financials
Cash vs Debt
Where AMRN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, AMRN finished 19.03% below its 150-day moving average ($14.24) and 20.15% below its 200-day moving average ($14.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AMRN overbought or oversold?
At the October 20, 2026 close, AMRN's RSI(14) was 14.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $314.6M in cash comfortably exceeding the $7.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$5.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -6.0%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $583.2M (2021) to $213.6M (2025), a 63% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Amarin Corporation plc's trajectory.